Breaking AI & Tech News Analyzed

A Historic Leap for Inclusive Space ExplorationThe UK Space Agency has signed a memorandum of understanding with US startup Vast to support the flight of John McFall. This agreement paves the way for McFall, a member of the European Space Agency (Esa) astronaut reserve, to become the first individual with a physical disability to live in orbit aboard the commercial Haven-1 station.The Haven-1 Mission and Commercial InfrastructureStation Specifications: Haven-1 is a commercial station smaller than a single-decker bus but capable of housing up to four astronauts.Features: The station includes a maplewood veneer interior, a domed observation window, and a laboratory for microgravity research.Transport: McFall will travel to the station via SpaceX's Crew Dragon capsule and Falcon 9 rocket.Timeline: The mission is proposed for 2027, with a duration of approximately two weeks.Research Scope: Prosthetics and Human PhysiologyThe core objective of McFall's mission extends beyond the symbolic achievement of being the first disabled astronaut. Scientifically, the flight will rigorously test how the space environment affects the human body and, crucially, how it impacts modern prosthetic limbs that rely on sensors and microprocessors. This data is vital for developing lighter, more adaptable prosthetics and improving rehabilitation programs for amputees on Earth.Shifting Paradigms in Disability and EmploymentBeyond the laboratory, McFall's presence challenges deep-seated societal preconceptions about the capabilities of people with disabilities. By demonstrating that individuals with physical limitations can perform complex tasks in zero gravity, the mission sets a precedent for inclusive employment across high-risk and high-skill industries. Tim Peake has already hailed this as a "landmark moment for inclusive human spaceflight."The Future of Commercial Spaceflight and InclusionIf McFall successfully launches in 2027, it will signal a new era for commercial space stations like Haven-1. The success of this mission could accelerate the integration of diverse candidates into space programs, moving beyond the traditional "astronaut" archetype. It also suggests a future where private companies drive inclusivity standards, potentially opening the door for more astronauts with disabilities to participate in long-duration missions to the ISS or commercial outposts.

On 15 May, **BioOrbit** launched its compact **Box‑E** payload aboard a **SpaceX** rocket, beginning a six‑week orbital trial to grow ultra‑pure protein crystals for self‑injectable cancer therapies. Box‑E’s Orbital Test: Microgravity Enables Ultra‑Pure Protein Crystals The microwave‑sized unit will float aboard the International Space Station, where microgravity eliminates the disruptive effects of Earth’s gravity on crystal formation. The resulting crystals are more stable, allowing drug formulations that are impossible to achieve on the ground. Mission duration: ~6 weeks in orbit Target output: thousands of litres of fluid per box per year Goal: Produce cancer‑drug crystals that can be stored in a fridge and self‑injected £9.8 Million Funding Round and UK Space Agency Contract Last month **BioOrbit** closed a **£9.8 million** Series A round led by **LocalGlobe** and **Breega**, earmarked for the orbital test and scaling of the hardware. Earlier in March the company secured a **£250,000** contract from the UK Space Agency to manufacture drugs in microgravity. Potential Disruption of Cancer Treatment Delivery Current immunotherapies such as Merck’s **Keytruda** require lengthy IV infusions in hospitals. By crystallising the active protein, **Box‑E** could enable high‑concentration, low‑viscosity formulations suitable for pen‑injectors, reducing treatment time from hours to minutes and extending shelf‑life. Roadmap to Commercialisation and Market Size **BioOrbit** projects that, if orbital tests succeed, multiple **Box‑E** units could be stacked to meet the demand of a blockbuster drug within a handful of boxes. The company estimates a market of **$22.7 trillion** for in‑space manufacturing across sectors, with pharmaceuticals a key segment. Clinical trials and regulatory approval are expected to take at least five years before the new formulations reach patients. Future Outlook for Space‑Based Pharma Beyond cancer, the crystallisation platform could be applied to the roughly 70 % of top‑selling drugs that are currently administered intravenously. Partnerships with major pharma groups are already being explored, and competitors such as **Varda Space Industries** are also pursuing in‑orbit drug processing, signaling a burgeoning industry.